M&A
Biossil Labs acquires Theriva's antibiotic degrader portfolio for up to $91M
Key Facts
Signal Type
M&A
Industry
Biotech
Companies
Biossil Labs, Theriva Biologics, OpenAI, Founders Fund, Summit Therapeutics
Date
Biossil Labs has acquired Theriva Biologics' portfolio of antibiotic-degrading enzymes for $350,000 upfront and up to $91 million in milestone payments — $3 million tied to regulatory progress and up to $88 million tied to worldwide net sales. Theriva is also eligible for up to $250 million in royalties at a low single-digit rate.
The portfolio is led by SYN-004, or ribaxamase, a prophylactic therapy that Theriva took through a phase 2b trial in patients receiving antibiotics for lower respiratory tract infection, showing gut microbiome maintenance and recovery, reduced incidence of Clostridioides difficile infection, and lower overall pathogen rates. Two preclinical oral candidates come with the deal: the ribaxamase reformulation SYN-007 and the antibiotic degrader carbenemase, or SYN-006.
Biossil inherits an active clinical program. The company will continue a phase 1b/2a study of SYN-004 in patients susceptible to graft-versus-host disease and other infections during hematopoietic cell transplant — a study Theriva had paused after completing two of three planned cohorts. That restart puts Biossil's clinical operations and regulatory functions in the market for trial execution support at short notice.
Theriva emerges with a narrower cost base and its remaining cash directed at VCN-01, an oncolytic adenovirus in early- to mid-stage trials for metastatic pancreatic ductal adenocarcinoma and refractory retinoblastoma. Vendors supporting the divested enzyme programs now face a counterparty change, while vendors supporting VCN-01 face a customer with a stated intent to concentrate spend.
Biossil is running a repeatable playbook: buy deprioritized or failed candidates cheaply and re-test them with AI-guided prioritization. This is its third such transaction in roughly a year, following a $105 million deal in July for a failed antibiotic from Summit Therapeutics and a $105 million biobucks agreement for dismutase mimetics from Galera Therapeutics, plus the sickle cell candidate rivipansel from Pfizer.
The immediate tell is whether Biossil restarts enrollment in the SYN-004 phase 1b/2a transplant study and on what timeline — that decision drives near-term demand for CRO, site, and regulatory support. Also watch how quickly the $3 million regulatory milestone tranche is triggered, since it signals how fast Biossil intends to move SYN-004 toward later-stage development.
On the Theriva side, watch whether the $350,000 upfront plus milestone structure is enough to extend the VCN-01 runway, and whether further asset sales follow. For Biossil, the question is whether a fourth acquisition lands before the current portfolio generates clinical readouts, and whether the AI-driven reprioritization thesis survives contact with phase 2b data it did not generate.
Source:
Fierce BiotechGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
